Biotech companies are scrambling to collaborate on the rapid development and deployment of products and services to address the COVID-19 pandemic. These collaborations are driving unprecedented investments and resources, hundreds of new clinical trials and partnerships for vaccines, therapeutics and diagnostics, and the deployment of resources for critical personal protective equipment (PPE), ventilators, and other equipment.
In this BioLabs@NYULangone webinar, I share guidance and tips for efficient biotech collaborations while balancing the challenges created by the pandemic.
Key sections I recommend watching:
- 6:45 – Threshold issues to consider when exploring new COVID-19 partnerships
- 10:40 – Heightened sensitivities around PR, valuation and investor-relations issues with COVID-19 projects
- 20:36 – Potential benefits in COVID-19 partnerships around ancillary companion diagnostic insights for drug and vaccine development
- 29:14 – Considering otherwise standard contractual provisions in a COVID-19 environment